Today: 30 April 2026
Browse Category

NYSE:NVO 6 November 2025 - 25 November 2025

US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

U.S. stock futures rose Monday, with Dow, S&P 500, and Nasdaq up 0.3% to 1% pre-market as traders bet on a possible December Fed rate cut. Bitcoin rebounded above $85,000, boosting crypto stocks. Novo Nordisk shares fell sharply after its Alzheimer’s trial failed. No major U.S. economic data is due today due to a government shutdown delay.
25 November 2025
···
BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

BIIB Stock Today: Biogen Hits New 52‑Week High After Novo Nordisk Alzheimer’s Trial Failure (Nov. 24, 2025)

Biogen shares hit a 52-week high Monday, closing at $177.42, up 1.2%, after Novo Nordisk’s Alzheimer’s drug failed in late-stage trials. The stock traded as high as $185.17 intraday on volume of about 2.07 million shares. Investors also reacted to Biogen’s new immunology partnership with Dayra Therapeutics. Novo shares fell sharply on the trial news.
24 November 2025
··
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk’s U.S. shares fell 1.1% to $47.07 by late morning, while Copenhagen B-shares closed down nearly 3% at DKK 305, extending a year-to-date drop of about 45%. Denmark compensated four patients for vision loss linked to Wegovy and Ozempic. Novo Nordisk and Eli Lilly launched direct-to-employer GLP-1 drug programs, and Novo cut self-pay prices for its weight-loss drugs.
21 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk’s U.S. ADR traded near $49 Thursday, steady after a 3% rebound, while Copenhagen shares rose about 2–2.5% to DKK 318–319. The company faces slowing GLP-1 demand, price cuts, and high-profile Alzheimer’s trials, with results expected December 3. Shares remain down over 10% in three months and nearly 46% year-to-date after guidance cuts.
20 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Novo Nordisk cut U.S. self-pay prices for Wegovy and Ozempic and launched a $199 two-month introductory offer for new patients. Shares fell 1.9% to $47.55 intraday as investors weighed pricing pressure and governance changes. Novo Holdings exited its 7.8% stake in ConvaTec in London. Trading volumes reached about 7.9 million shares by 16:12 UTC.
18 November 2025
··
LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD (LFMD) Slashes Wegovy and Ozempic Cash-Pay Price to $199 as Q3 2025 Earnings and GLP‑1 Price War Heat Up

LifeMD announced $199 monthly cash-pay pricing for starter doses of Wegovy and Ozempic, available to new patients for their first two fills through its Weight Management Program. The move follows a partnership with Novo Nordisk and comes hours before LifeMD’s delayed Q3 2025 earnings release, rescheduled for Nov. 17. LFMD shares traded around $4.60 this afternoon, slightly down despite the news.
17 November 2025
··
Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio shares plunged nearly 80% to around $6.60 in pre-market trading Thursday after the company reported mixed early data from its lead RNA-editing program, KRRO‑110, and announced layoffs, a pipeline shift, and a year-long pause in its Novo Nordisk partnership. The Phase 1/2a trial showed KRRO‑110 increased AAT protein but did not reach protective levels.
13 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

WeightWatchers plans to offer Novo Nordisk’s oral Wegovy in the U.S. after its expected 2026 launch. Sandoz says unbranded Ozempic could reach Canada by June 2026, intensifying price competition. CVS dropped Lilly’s Zepbound from its preferred list, keeping Wegovy, prompting Lilly to move employees off CVS plans. Novo Nordisk shares traded at $49.76 late Wednesday, up slightly.
12 November 2025
·····
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera shares fell about 15% Monday after the company accepted Pfizer’s revised takeover offer, ending a bidding war with Novo Nordisk. Pfizer will pay $65.60 per share in cash plus up to $20.65 in contingent value rights. Novo withdrew its bid over the weekend. Metsera cited U.S. FTC antitrust concerns with Novo’s proposal.
10 November 2025
····
Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

Stocks to Watch Today (Nov. 10, 2025): Nvidia Rebounds; Pfizer Clinches Metsera; Novo Nordisk Rises; Rumble Soars on AI Deal; Tyson Foods Guides Higher

U.S. stock futures rose Monday as Senate action fueled hopes for an end to the government shutdown, with Nvidia up 3% premarket. Pfizer won the $10 billion Metsera bid, sending Novo Nordisk shares higher in Copenhagen. Rumble agreed to buy Germany’s Northern Data in an all-stock deal, gaining access to 22,400 Nvidia GPUs. Tyson Foods raised its FY2026 revenue outlook as chicken sales offset beef weakness.
10 November 2025
····
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Novo Nordisk and Pfizer Stocks Today (Nov. 10, 2025): Pfizer Clinches $10B Metsera Deal as Novo Rises on Exit and India Brand Move

Pfizer will acquire obesity drug developer Metsera in a deal worth up to $10 billion, with a shareholder vote set for Nov. 13. Novo Nordisk shares rose after it exited the bidding. Norway’s $1.5 trillion sovereign wealth fund said it will abstain from voting on Novo’s new board at a meeting Nov. 14. Novo also signed a deal to distribute its semaglutide weight-loss shot in India under the brand Poviztra.
10 November 2025
··
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer Clinches $10B Takeover of Metsera as Novo Nordisk Bows Out — Full Terms, Timeline, and What It Means (Nov. 8, 2025)

Metsera agreed to Pfizer’s revised takeover offer worth up to $10 billion after Novo Nordisk withdrew from bidding. The deal values Metsera at $86.25 per share, including $65.60 in cash and up to $20.65 via a contingent value right. Metsera shareholders will vote on the merger November 13. Both companies expect a swift closing if approved.
8 November 2025
····
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Pfizer secured a deal to acquire obesity-drug developer Metsera for up to $10 billion after Novo Nordisk withdrew its rival bid, citing FTC antitrust concerns. Metsera shareholders are set to vote Nov. 13 on Pfizer’s offer of $65.60 in cash plus up to $20.65 per share in contingent value rights. Metsera’s board recommended approval. Metsera shares surged nearly 60% during the bidding.
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer will acquire Metsera for up to $10 billion after Metsera accepted a revised cash-and-CVR offer late Friday, ending Novo Nordisk’s competing bid. Metsera’s board cited U.S. antitrust risks with Novo’s proposal following FTC feedback. Pfizer will pay $65.60 per share plus a contingent value right of up to $20.65. A shareholder vote is set for Nov. 13, with closing expected soon after.
8 November 2025
···
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer agreed to acquire Metsera for up to $10 billion, outbidding Novo Nordisk and ending a heated takeover battle. Metsera shareholders will vote on the deal Nov. 13, with closing expected soon after pending approvals. Shares of MTSR surged to $83.18 following the announcement. Regulators are expected to review the deal’s impact on the obesity-drug market.
8 November 2025
·····
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer (PFE) Stock Today — Nov 7, 2025: Metsera Bidding War Intensifies, Dividend Record Date, and What’s Moving the Share Price

Pfizer shares fell 2.3% to $24.28 amid heavy trading as a Delaware judge allowed Metsera to exit its deal with Pfizer, intensifying the takeover battle with Novo Nordisk. Pfizer is reportedly considering a higher bid ahead of Metsera’s Nov. 13 shareholder vote. The company marked its dividend record date today for a $0.43 payout. Earlier this week, Pfizer raised its 2025 EPS guidance after beating Q3 estimates.
7 November 2025
····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 7, 2025): NVO Slips as U.S. Wegovy/Ozempic Price Cuts Take Center Stage; Medicare Coverage, FTC Scrutiny and Metsera Bid in Focus

Novo Nordisk shares fell about 2–4% Friday after the company and Eli Lilly agreed to cut U.S. prices for GLP‑1 drugs, including Medicare coverage, reducing monthly costs to $149–$350. Novo expects a low single-digit hit to global sales growth in 2026. A Delaware court backed Novo’s bid for Metsera, while U.S. regulators flagged antitrust concerns. Novo missed Q3 estimates and lowered its full-year outlook.
7 November 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

Novo Nordisk shares fell about 2.4% after the White House announced a deal with Novo and Eli Lilly to expand Medicare coverage and lower prices for anti-obesity drugs. The agreement includes a Medicare Part D pilot starting in 2026, lower prices in Medicare, Medicaid, and cash channels, and a three-year tariff exemption. Novo expects a low single-digit hit to 2026 global sales growth. NVO traded at $47.30 as of 12:51 p.m. ET.
6 November 2025
··
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (Nov 6, 2025): NVO steadies as White House GLP‑1 pricing deal lands; $10B Metsera bidding war heats up

Novo Nordisk ADRs closed at $47.36, down from a $47.75 open, after news of a White House deal to cut GLP-1 drug prices and expand Medicare/Medicaid access. The company confirmed lower U.S. prices and a pilot for Medicare Part D obesity drug coverage. Novo is also in a $10 billion bidding war with Pfizer for obesity-drug maker Metsera. Volume topped 29 million shares.
6 November 2025
·
1 … 3 4 5 6 7

Stock Market Today

  • Social Security Faces 2033 Benefits Cliff Amid Debate Over S&P 500 Gains
    April 30, 2026, 12:13 PM EDT. A 64-year-old retiree's claim that Social Security payroll taxes could have grown into a $4 million S&P 500 investment revives debates on the program's future. The Old-Age and Survivors Insurance Trust Fund (OASI) is projected to run dry by 2033, with only 77% of scheduled benefits payable thereafter. Unlike investment accounts, Social Security funds are invested conservatively in U.S. government securities to minimize risk. Experts warn shifting to stock market investments could raise fees and add volatility, risking the system's reliability. The core issue remains solvency, as the system faces increasing financial pressure amidst uncertain market conditions and global events.

Latest article

Social Security’s $4 Million Question: Can the S&P 500 Beat a 2033 Benefits Cliff?

Social Security’s $4 Million Question: Can the S&P 500 Beat a 2033 Benefits Cliff?

30 April 2026
A retiree’s claim that Social Security payroll taxes could have grown to $4 million in the S&P 500 has renewed debate over the system’s structure. The Social Security Administration projects its main trust fund will be depleted by 2033, with incoming revenue covering 77% of benefits. The fund invests only in government securities, not stocks. The payroll tax rate is set at 12.4% of earnings up to $184,500 in 2026.
Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

Everspin Technologies Stock Surges After $40 Million Defense MRAM Deal Puts Growth Back in View

30 April 2026
FatPipe shares jumped 18% to $2.92 Thursday after the company announced expanded access to its SD-WAN and cybersecurity products through public-sector procurement channels. The move follows a VeloCloud replacement program targeting customers of Arista Networks’ SD-WAN business. Trading volume reached 42.2 million shares. Investors remain cautious over execution and customer concentration risks.
Go toTop